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Select: The Many Faces of CancerAlthough cancer is typically viewed as a consequence of unregulated cell proliferation, it has
become increasingly clear that it also reflects a crisis of cellular identity. In this Select, we highlight
recent papers that may help us to unravel the multiple personalities of tumor cells and, in doing so,
bring us closer to conquering cancer in the clinic.Human tumor cells generate human
blood vessels when transplanted into
a mouse (human CD144 depicted in
red). Image courtesy of M. Todaro and
R. De Maria.DIY Plumbing for Glioblastoma
Stimulating the formation of new blood vessels confers a selective advantage on
tumor cells and is therefore a valuable therapeutic target. It’s currently thought that
in general, cancer cells ‘‘contract out’’ angiogenesis to noncancerous endothelial
cells, which are recruited by tumor-derived proteins such as vascular endothelial
growth factor (VEGF). However, two recent studies show that glioblastoma takes
a radically different approach to building new blood vessels.
Wang et al. (2010) and Ricci-Vitiani et al. (2010) show that the unusual vascular
tissue of these aggressive brain tumors contains a subpopulation of cells derived
directly from the tumor itself, not the surrounding endothelium, and that these cells
share the same mutational profile as the parent tumor. The teams also show that
a fraction of human glioblastoma cells can differentiate into endothelial cells in vitro
and, importantly, form tumors with human vasculature when transplanted into
mice. This human-derived vascular tissue appears to support tumor growth, as selec-
tive ablation of these cells in mice results in a significant reduction in tumor size.
Understanding the tumor origins of glioblastoma blood vessels might explain why
current angiogenesis inhibitors often fail to make an impact on tumor growth and
will likely lead to more effective means of targeting angiogenesis in the future.
Ricci-Vitiani, L., et al. (2010). Nature 468, 824–828.
Wang, R., et al. (2010). Nature 468, 829–833.A transplant of larval
brain tissue from l(3)
mbt mutant flies grows
dramatically in the adult
fly and depends on
the expression of germ-Back to the Germline
Gene expression profiling is a powerful tool to tease out themany different changes in cellular identity
that shape the development of a tumor. Janic et al. (2010) now use aDrosophila brain tumor model to
identify changes in gene expression driving the acquisition of cancer cell identity. Flies with a temper-
ature-sensitive mutation in the lethal (3) malignant brain tumor (l(3)mbt) gene develop very large
malignant growths in the larval brain. The gene encodes a transcriptional repressor that is thought
to act with retinoblastoma (RB) and HP1 to trigger nucleosome compaction and gene silencing. In
order to determine which genes are regulated by this silencing factor, Janic et al. compare the
gene expression profile of l(3)mbt larval brains with those of a panel of controls. This panel contains
not only brains without tumors but also brains from a different Drosophila brain tumor line (brat). By
comparing the genes that are differentially expressed in each tumor, they can remove a large number
of genes that are required for cell proliferation and focus on the remaining candidates that may define
tumor cell identity.
Remarkably, a quarter of these genes encode proteins that are normally expressed specifically in
germline cells. Upregulation of some of these genes in larval brain tumors appears to be important for
tumor growth, as flies that carry mutations in both l(3)mbt and several germline-specific genes fail to
develop brain overgrowth. Inactivation of these germline genes does not inhibit tumor growth in
a differentDrosophila brain tumormodel, suggesting that this soma-to-germline transition is not likely
to be a global signature of tumor cells. However, a number of human tumors, including melanoma
and several carcinomas, are known to upregulate germline-specific genes. This study suggests
that germline genes may play a more important role in tumor growth than previously thought.
Janic, A., et al. (2010). Science 330, 1824–1827.line-specific genes.
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Two subtypes of medulloblastoma have distinct
developmental origins. Image courtesy of R. Gil-
bertson.A Tale of Two Tumors
Around 25% of medulloblastomas originate from cerebellar granule neuron
precursors and are characterized by aberrant activation of the Sonic
Hedgehog pathway. However, very little is known about the molecular
underpinnings of the remaining cases. Gibson et al. (2010) now show that
some of the variation between different medulloblastomas is likely to be
due to their having very distinct developmental origins.
By taking advantage of the Brain Explorer 2 Gene Atlas, a three-dimen-
sional map of gene expression patterns in the mouse brain, Gibson et al.
searched for brain regions that express the signature genes of a different
form of medulloblastoma, known as the WNT-subtype. This form is charac-
terized by activating mutations in catenin b1 (CTNNB1) and tends to arise inolder children comparedwith the SHH-subtype. Unexpectedly,WNT-subtype signature genes tend to be expressed not in the
cerebellum but in the dorsal brainstem. Moreover, mice with a conditional activating mutation in Ctnnb1 fail to generate
tumors in the cerebellum but develop hyperplastic growths in the dorsal brainstem. If activation of Ctnnb1 is combined
with inactivation of p53, fully developedmedulloblastomas form. Thesemouse tumors are astonishingly similar to their human
WNT-subtype counterparts, in terms of histology, gene expression profile, and even specific chromosomal deletions. Iden-
tifying the cell type of origin of this tumor subtype has therefore led directly to the development of an accuratemousemodel of
the disease. In general, this kind of approach is likely to become increasingly widely used to developmore specific treatments,
allowing us to attack cancer at its bewilderingly diverse roots.
Gibson, P., et al. (2010). Nature 468, 1095–1099.Silencing Antitumor Immunity
Attempts to stimulate antitumor immunity have so far failed to make a significant impact. Even though these treatments are
often successful in raising a systemic immune reaction, they tend to have a limited effect on tumor growth, which suggests
that tumors have means of evading the immune response. Now, Kraman et al. (2010) show that a population of stromal cells
within tumors is responsible for defending cancer from attack by the immune system.
Cells expressing fibroblast activation protein-alpha (FAP-a) are thought to play a role in wound healing by preventing an
inappropriate immune response at the site of injury. Kraman et al. identify a small population of FAP-a-positive cells within
lung carcinomas and pancreatic adenocarcinomas. Despite being relatively sparse, these cells appear to exert a powerful
effect on the tumor microenvironment. Specific deletion of the FAP-a subpopulation is associated with a dramatic increase
in the efficacy of therapeutic immunization against a tumor antigen, resulting in hypoxic necrosis of the tumor. This response
occurs rapidly and locally and depends on the immune system, as it fails to occur in immunodeficient Rag2 mutant mice.
The exact basis of this reaction, however, remainsmysterious. Although antibodies against TNF-a and IFN-g are effective in
blocking the antitumor response, there are no significant changes in the level of these and other inflammatory cytokines
following deletion of FAP-a-positive cells. This suggests that suppression of antitumor immunity involves attenuation of
the surrounding cells’ sensitivity to cytokines, rather than inhibition of their expression or secretion. Armed with this knowl-
edge, it may now be possible to enhance the effectiveness of therapeutic vaccination strategies for cancer.
Kraman, M., et al. (2010). Science 330, 827–830.
Niki ScaplehornCell 144, January 21, 2011 ª2011 Elsevier Inc. 165
